Nuvalent Inc (NUVL) Reports Prelim Phase 1 Data from ALKOVE-1 Trial, Supports Best-In-Class Potential of NVL-655 Oct 13, 2023 06:30AM
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC Oct 13, 2023 06:30AM
Nuvalent (NUVL) Says Prelim. Phase 1 Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Pre-Treated Patients with ALK-Positive NSCLC and ALK-Selective, TRK-Sparing Safety Profile Oct 4, 2023 12:24PM
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile Oct 4, 2023 12:21PM
Nuvalent Inc (NUVL) to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 Sep 18, 2023 06:30AM
View Older Stories

Sep 18, 2023 06:30AM Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Sep 5, 2023 06:31AM Nuvalent Inc (NUVL) Initiates Phase 2 Portion of ARROS-1 Clinical Trial
Sep 5, 2023 06:30AM Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Aug 31, 2023 06:30AM Nuvalent to Participate in Upcoming September Investor Conferences
Aug 10, 2023 06:30AM Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
Aug 1, 2023 06:30AM Nuvalent to Participate in Upcoming August Investor Conferences
May 24, 2023 06:30AM Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 11, 2023 06:31AM Nuvalent Inc (NUVL) Plans to Report Preliminary Phase 1 Dose-Escalation Data for NVL-655 in H2'23; Reports Q1
May 11, 2023 06:30AM Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
Apr 19, 2023 06:30AM Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
Apr 18, 2023 09:09AM Nuvalent Inc (NUVL) Presents New Preclinical Data Supporting NVL-655
Apr 18, 2023 09:00AM Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
Mar 23, 2023 06:31AM Nuvalent Inc (NUVL) to Present ALKOVE-1 Trial in Progress
Mar 23, 2023 06:30AM Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
Mar 16, 2023 06:30AM Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 14, 2023 05:59PM Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
Mar 1, 2023 06:30AM Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
Jan 4, 2023 06:30AM Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 13, 2022 10:15AM Nuvalent Inc (NUVL) Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
Dec 13, 2022 10:15AM Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
Nov 10, 2022 06:30AM Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
Oct 28, 2022 03:50AM Nuvalent (NUVL) Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial
Oct 28, 2022 12:01AM Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
Oct 26, 2022 06:31AM Nuvalent Inc (NUVL) Reports New Preclinical Data for NVL-330 and NVL-655
Oct 26, 2022 06:30AM Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
Oct 17, 2022 06:30AM Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
Oct 6, 2022 06:31AM Nuvalent Inc (NUVL) Appoints Michael L. Meyers to its Board
Oct 6, 2022 06:30AM Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
Sep 7, 2022 06:36AM Nuvalent Inc (NUVL) to Present Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at ENA
Sep 7, 2022 06:30AM Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates
Sep 1, 2022 06:30AM Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
Aug 10, 2022 06:30AM Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
Aug 5, 2022 06:31AM Nuvalent Inc (NUVL) Reports Preclinical Data Supporting Potential Best-in-Class Profile for Inhibitor NVL-655
Aug 5, 2022 06:30AM Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
Aug 3, 2022 06:30AM Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
Jul 20, 2022 06:30AM Nuvalent Inc (NUVL) Promotes Darlene Noci to Chief Development Officer
Jul 20, 2022 06:30AM Nuvalent Announces Leadership Promotions
Jul 13, 2022 06:30AM Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
Jun 21, 2022 07:17AM Nuvalent Inc (NUVL) Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
Jun 21, 2022 06:30AM Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
Jun 2, 2022 06:38AM Nuvalent to Present at the 2022 Jefferies Healthcare Conference
May 12, 2022 06:30AM Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
Apr 8, 2022 01:20PM Nuvalent Inc (NUVL) Presents Expanded Data Showing Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR
Apr 8, 2022 01:15PM Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
Apr 7, 2022 06:30AM Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
Mar 31, 2022 06:31AM Nuvalent (NUVL) Appoints Anna Protopapas as Chair of Board of Directors
Mar 31, 2022 06:30AM Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
Mar 29, 2022 06:31AM Nuvalent Inc (NUVL) Reports Pipeline and Business Progress, Announces Q4 Results
Mar 29, 2022 06:30AM Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
Mar 8, 2022 05:38PM Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
View Older Stories